Altheome is a specialist bioanalysis CRO delivering ultra-sensitive, disease-agnostic biomarker assay development, validation, sample analysis, and custom assay development for pharmaceutical, biotech, and academic partners. We combine ultra-sensitive immunoassay platforms with next-generation, high-plex proteomics, giving us both targeted precision and broad discovery coverage across inflammatory, neurological, oncology, and metabolic biology.
Beyond serum and plasma, our recent work has pushed high-plex profiling into non-traditional matrices and collection methods, including microneedle-sampled dermal interstitial fluid and exhaled breath condensate, to understand how biomarker signals behave outside conventional sample types.
We work across the discovery-to-translation pipeline, from protocol design and assay optimisation through to analysis and data interpretation, with specialist depth in brain, gut, inflammatory, and cardiovascular biology.
